×
About 2,688 results

ALLMedicine™ Allergic Conjunctivitis Center

Research & Reviews  444 results

Allergic conjunctivitis and contact dermatitis following silicone tube intubation.
https://doi.org/10.1016/j.jcjo.2022.06.017
Canadian Journal of Ophthalmology. Journal Canadien D'oph... Chen T, Roelofs KA et. al.

Jul 23rd, 2022 - Allergic conjunctivitis and contact dermatitis following silicone tube intubation.|2022|Chen T,Roelofs KA,Rootman DB,|

Impaired sleep quality in children with allergic conjunctivitis and their parents.
https://doi.org/10.1038/s41433-022-02182-4
Eye (London, England); Li J, Zhang SY et. al.

Jul 23rd, 2022 - To investigate the sleep quality in children with allergic conjunctivitis (AC) and their parents. Prospective, case-controlled study. Zhongshan Ophthalmic Center, a tertiary referral centre. Participants comprised 73 children aged 4-12 years with ...

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05314621

Jul 20th, 2022 - At Visit 1, subjects will sign the informed consent and an allergic skin test will be performed, if required. Each qualifying subject will undergo a bilateral conjunctival allergen challenge (Ora-CAC®) titration using an allergen they had a positi...

Characteristics of histamine H4 receptor agonist-induced allergic conjunctivitis model ...
https://doi.org/10.1016/j.vascn.2022.107203
Journal of Pharmacological and Toxicological Methods; Mochizuki H, Suyama S et. al.

Jul 17th, 2022 - Histamine is strongly associated with the onset of allergic conjunctivitis. The most recent cloned histamine H4 receptor antagonist is highly expected as a new therapeutic drug candidate. As a model for a therapeutic drug targeting the histamine H...

A Rapid and Sensitive Determination of Histamine in Mast Cells Using a Didansyl Derivat...
https://doi.org/10.1159/000525588
International Archives of Allergy and Immunology; Asai H, Yamamoto R et. al.

Jul 11th, 2022 - Mast cells play a central role in allergic responses such as food allergy, asthma, allergic rhinitis, and allergic conjunctivitis. Symptoms in the early phase of these allergic diseases are primarily caused by histamine. However, due to the high h...

see more →

Drugs  461 results see all →

Clinicaltrials.gov  119 results

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05314621

Jul 20th, 2022 - At Visit 1, subjects will sign the informed consent and an allergic skin test will be performed, if required. Each qualifying subject will undergo a bilateral conjunctival allergen challenge (Ora-CAC®) titration using an allergen they had a positi...

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05234554

May 10th, 2022 - The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seaso...

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05265910

May 3rd, 2022 - This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated c...

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
https://clinicaltrials.gov/ct2/show/NCT04622345

Apr 27th, 2022 - The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT04708821

Apr 13th, 2022 - This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjun...

see more →

News  49 results

Unilateral eye irritation
https://www.mdedge.com/familymedicine/article/254196/unilateral-eye-irritation
MDedge Family Medicine;

Apr 28th, 2022 - Physical examination revealed an irregularly shaped conjunctival cyst on the lateral (temporal) field of the right eye. (This diagnosis is usually made based on the clinical examination alone.

First Drug-Eluting Contact Lens Wins FDA Nod
https://www.medpagetoday.com/allergyimmunology/allergy/97480

Mar 3rd, 2022 - A drug-eluting contact lens containing an antihistamine for people with allergic eye itch won approval from the FDA, Johnson & Johnson Vision Care announced. The daily disposable etafilcon A drug-eluting contact lens with ketotifen (Acuvue Theravi...

FDA Approvals, Highlights, and Summaries: Ophthalmology 
https://www.medscape.com/viewarticle/967614

Feb 17th, 2022 - Tyrvaya (varenicline intranasal) Varenicline intranasal is indicated for treatment of signs and symptoms of dry eye disease. Varenicline binds to highly selective heteromeric subtype(s) of the nicotinic acetylcholine receptor, which produces agoni...

FDA Approvals, Highlights, and Summaries: Ophthalmology 
https://reference.medscape.com/viewarticle/967614

Feb 17th, 2022 - Tyrvaya (varenicline intranasal) Varenicline intranasal is indicated for treatment of signs and symptoms of dry eye disease. Varenicline binds to highly selective heteromeric subtype(s) of the nicotinic acetylcholine receptor, which produces agoni...

One in 15 Patients Who Start Dupilumab May Develop Conjunctivitis, Large Analysis Finds
https://www.medscape.com/viewarticle/953387

Jun 18th, 2021 - One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. "About 4 years after dupilumab's ap...

see more →

Patient Education  2 results see all →